Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimoclomol

Drug Profile

Bimoclomol

Alternative Names: ABT 822; BRLP 42

Latest Information Update: 23 May 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biorex
  • Class Anti-ischaemics; Antihyperglycaemics; Small molecules
  • Mechanism of Action Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic complications; Diabetic neuropathies; Ischaemic heart disorders

Most Recent Events

  • 17 May 2011 Orphazyme acquires bimoclomol from CytRx Corporation
  • 12 Oct 2004 CytRx Corporation has acquired all the clinical, pharmacological and intellectual property assets of Biorex
  • 04 Dec 2001 Abbott Laboratories returned all rights to bimoclomol to Biorex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top